Oncology Reviews最新文献_第10页

Prospects for repurposing CNS drugs for cancer treatment. 中枢神经系统药物用于癌症治疗的前景。

IF 3.6

Oncology Reviews Pub Date : 2019-04-17 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.411

Mohamed Abdelaleem, Hossam Ezzat, Muhammed Osama, Adel Megahed, Waleed Alaa, Ahmed Gaber, Ayman Shafei, Alaa Refaat

引用次数: 22

Adherence to oral pharmacological treatment in cancer patients: Systematic review. 癌症患者口服药物治疗的依从性:系统评价。

IF 3.6

Oncology Reviews Pub Date : 2019-04-16 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.402

Melissa Perdomo Claros, Claudia Viviana Marín Messa, Herney Andrés García-Perdomo

{"title":"Adherence to oral pharmacological treatment in cancer patients: Systematic review.","authors":"Melissa Perdomo Claros, Claudia Viviana Marín Messa, Herney Andrés García-Perdomo","doi":"10.4081/oncol.2019.402","DOIUrl":"https://doi.org/10.4081/oncol.2019.402","url":null,"abstract":"The objective was to identify the best-validated scale for assessing oral pharmacological adherence in oncology patients. A bibliographic search was performed in MEDLINE via Ovid, EMBASE, CENTRAL and LILACS. We included all studies in which a validation of adherence scales to oral pharmacological treatment was performed in oncology patients older than 18 years without gender distinction. We excluded studies that included newly diagnosed patients. No statistical analysis was performed due to the nature of the study. A total of 4609 studies were found. After screening, six studies were selected for qualitative analysis. In the analysis of the six included studies, a total of 855 patients older than 18 years with oncological diagnoses were found. Two of the studies, Bagcivan et al. and Amorim et al., used scales that show acceptable validity and reliability to adequately measure adherence to pharmacological treatment in each of the patients. In this way, the quality of patient care and success in pharmacological treatments can be guaranteed. According to the results obtained in the evaluation of biases and analysis of psychometric properties, the best-validated scales are as follows: Adherence Determinants Questionnaire (ADQ) (Brazilian version) and the Oral Chemotherapy Adherence Scale (OCAS). These are valid, reliable and useful scales that can be adapted to any cultural context.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"402"},"PeriodicalIF":3.6,"publicationDate":"2019-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.402","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37204653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

A comprehensive overview of mitochondrial DNA 4977-bp deletion in cancer studies. 线粒体DNA 4977-bp缺失在癌症研究中的全面概述。

IF 3.6

Oncology Reviews Pub Date : 2019-04-16 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.409

Abdul Aziz Mohamed Yusoff, Wan Salihah Wan Abdullah, Siti Zulaikha Nashwa Mohd Khair, Siti Muslihah Abd Radzak

引用次数: 32

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. 骨髓增生异常综合征的复杂核型:诊断程序和预后易感性。

IF 3.6

Oncology Reviews Pub Date : 2019-02-04 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.389

Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi

{"title":"Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.","authors":"Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi","doi":"10.4081/oncol.2019.389","DOIUrl":"https://doi.org/10.4081/oncol.2019.389","url":null,"abstract":"Complex karyotype (CK) is a poor prognosis factor in hematological malignancies. Studies have shown that the presence of CK in myelodysplastic syndrome (MDS) can be associated with MDS progression to acute myeloid leukemia. The goal of this review was to examine the relationship between different types of CK with MDS, as well as its possible role in the deterioration and progression of MDS to leukemia. The content used in this paper has been obtained by a PubMed and Google Scholar search of English language papers (1975-2018) using the terms complex karyotype and myelodysplastic syndromes. A single independent abnormality can be associated with a good prognosis. However, the coexistence of a series of abnormalities can lead to CK, which is associated with the deterioration of MDS and its progression to leukemia. Therefore, CK may be referred to as a prognostic factor in MDS. The detection of independent cytogenetic disorders that altogether can result in CK could be used as a prognostic model for laboratory and clinical use.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"389"},"PeriodicalIF":3.6,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Advances in pancreatic cancer biomarkers. 胰腺癌生物标志物研究进展

IF 3.6

Oncology Reviews Pub Date : 2019-02-01 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.410

Syed Hasan, Rojymon Jacob, Upender Manne, Ravi Paluri

引用次数: 82

Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment. 接受化疗的患者的生理病理和心脏毒性诊断。

IF 3.1

Oncology Reviews Pub Date : 2019-02-01 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.383

Filipe C Marmelo, Cátia F R Sá

引用次数: 0

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. 硼替佐米治疗复发或难治性多发性骨髓瘤患者的现实环境

IF 3.6

Oncology Reviews Pub Date : 2019-01-18 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.377

Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang

{"title":"Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.","authors":"Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang","doi":"10.4081/oncol.2019.377","DOIUrl":"https://doi.org/10.4081/oncol.2019.377","url":null,"abstract":"Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM. The primary endpoints included clinical effectiveness outcomes (disease response, disease progression [PD], time-to-response, time-toprogression, response duration, and overall survival [OS]). Secondary endpoints were safety and healthcare resource utilization. Total 100 patients (median [range] age 64.9 [37.0-85.5] years) were enrolled; 47 patients completed the study. Of the withdrawn patients (n=53), there were 48 deaths (PD-related death: n=35, adverse events [AEs]-related: n=12, other reason: n=1), and 5 due to loss to follow-up. Four patients in Cycle 1, 6 patients each in Cycle 2 and 5, 7 in Cycle 3, 10 patients in Cycle 4, 5 patients in Cycle 6, and 3 patients each in Cycle 7 and 8 achieved overall response during the study. Time-to-response was 4.68 months (95%CI: 3.2, NE) and response duration was 10.08 months (95%CI: 2.3, 28.6). Median OS was 9.8 months (95%CI: 3.8, 13.7), and median time-to-progression was 11.3 months (95%CI: 6.2, 20.2). Most common non-hematological AEs were diarrhea (n=32) and hypoesthesia (n=25); most common hematological AE was thrombocytopenia (n=18). Efficacy and safety profile of bortezomib in Taiwanese patients with MM was similar to global and other Asian population. Study provides a critical insight on use of bortezomib in realworld clinical practice, which can be helpful for Taiwanese healthcare providers' decision-making processes.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"377"},"PeriodicalIF":3.6,"publicationDate":"2019-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature. 宫颈癌伴肾积水患者的生存结局:文献系统综述。

IF 3.6

Oncology Reviews Pub Date : 2019-01-15 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.387

Vasilios Pergialiotis, Ioannis Bellos, Nikolaos Thomakos, Dimitrios Haidopoulos, Despina N Perrea, Konstantinos Kontzoglou, Georgios Daskalakis, Alexandros Rodolakis

{"title":"Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature.","authors":"Vasilios Pergialiotis, Ioannis Bellos, Nikolaos Thomakos, Dimitrios Haidopoulos, Despina N Perrea, Konstantinos Kontzoglou, Georgios Daskalakis, Alexandros Rodolakis","doi":"10.4081/oncol.2019.387","DOIUrl":"https://doi.org/10.4081/oncol.2019.387","url":null,"abstract":"Hydronephrosis is a sign of advanced stage disease in patients with cervical cancer. Its presence is believed to negatively affect the survival of patients. To date, however, consensus in this field is still lacking. The purpose of the present systematic review is to gather the available data and to provide directions for future research in the field. We systematically searched Medline, Scopus, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials CENTRA and Google Scholar databases from inception till June 2018. Overall, 22 studies were included in the present systematic review that evaluated outcomes from 8521 patients with cervical cancer. The findings of our systematic review support that hydronephrosis negatively affects the overall survival of cervical cancer patients. Specifically, the reported 5- year OS hazards ratio for hydronephrosis ranged between 1.34 and 3.74. Outcomes concerning the disease-free survival of these patients were, however, less discrete. None of the included studies reported whether the decreased survival of patients with hydronephrosis was attributed to complications of obstructive uropathy such as uremia and sepsis. Thus, it remains, to date, unclear whether placement of ureteral stents or percutaneous nephrostomy may actually benefit these patients. More studies are needed to evaluate the actual impact of hydronephrosis on survival rates at the various stages of cervical cancer and to help establish consensus regarding the optimal mode of management of these patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"387"},"PeriodicalIF":3.6,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36952674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Breast cancer, human immunodeficiency virus and highly active antiretroviral treatment; implications for a high-rate seropositive region. 癌症、人类免疫缺陷病毒和高活性抗逆转录病毒治疗；对高血清阳性区域的影响。

IF 3.6

Oncology Reviews Pub Date : 2019-01-14 DOI: 10.4081/oncol.2019.376

Subash Chirkut

引用次数: 0

Myelodysplastic syndrome from theoretical review to clinical application view. 骨髓增生异常综合征从理论综述到临床应用。

IF 3.6

Oncology Reviews Pub Date : 2018-12-07 DOI: 10.4081/oncol.2018.397

Amrallah A Mohammad

引用次数: 25